Point-of-care biosensor systems for cancer diagnostics/prognostics
Loading...
Collections
Author/Creator ORCID
Date
2006-02-13
Type of Work
Department
Program
Citation of Original Publication
Soper, Steven A.; Brown, Kathlynn; Ellington, Andrew; Frazier, Bruno; Garcia-Manero, Guillermo; Gau, Vincent; Gutman, Steven I.; Hayes, Daniel F.; Korte, Brenda; Landers, James L.; Larson, Dale; Ligler, Frances; Majumdar, Arun; Mascini, Marco; Nolte, David; Rosenzweig, Zeev; Wang, Joseph; Wilson, David; Point-of-care biosensor systems for cancer diagnostics/prognostics; Biosensors and Bioelectronics, Volume 21, Issue 10, 15 April 2006, Pages 1932-1942; https://www.sciencedirect.com/science/article/abs/pii/S0956566306000121?via%3Dihub#!
Rights
This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Public Domain Mark 1.0
This work was written as part of one of the author's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.
Public Domain Mark 1.0
This work was written as part of one of the author's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.
Subjects
Abstract
With the growing number of fatalities resulting from the 100 or so cancer-related diseases, new enabling tools are required to provide extensive molecular profiles of patients to guide the clinician in making viable diagnosis and prognosis. Unfortunately with cancer-related diseases, there is not one molecular marker that can provide sufficient information to assist the clinician in making effective prognoses or even diagnoses. Indeed, large panels of markers must typically be evaluated that cut across several different classes (mutations in certain gene fragments—DNA; over/under-expression of gene activity as monitored by messenger RNAs; the amount of proteins present in serum or circulating tumor cells). The classical biosensor format (dipstick approach for monitoring the presence of a single element) is viewed as a valuable tool in many bioassays, but possesses numerous limitations in cancer due primarily to the single element nature of these sensing platforms. As such, if biosensors are to become valuable tools in the arsenal of the clinician to manage cancer patients, new formats are required. This review seeks to provide an overview of the current thinking on molecular profiling for diagnosis and prognosis of cancers and also, provide insight into the current state-of-the-art in the biosensor field and new strategies that must be considered to bring this important technology into the cancer field.